证券代码：688580 证券简称：伟思医疗 公告编号：2025-046 南京伟思医疗科技股份有限公司 第四届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 因公司位于南京市雨花台区硕果路 1 号的"伟思医疗总部研发经济园"已顺 利完成竣工验收，具备成熟高效的办公及运营条件，计划于 2026 年上半年完成 整体搬迁。新总部集高端研发、智能制造与现代化办公于一体，在办公环境、生 产承载能力、研发基础设施及智能化水平等方面均显著优于现有场所，将为公司 高质量发展提供有力支撑。 为优化资产结构、提升资源配置效率并增强资金流动性，公司拟处置现办公 总部——南京市雨花台区宁双路 19 号 9 幢的房屋建筑物及附属固定资产。经与 1 交易对方江苏云智汇创业投资有限公司协商一致，本次资产转让含税总价为人民 币 11,900 万元（大写：壹亿壹仟玖佰万元整）。 一、董事会会议召开情况 南京伟思医疗科技股份有限公司（以下简称"公司"）第四届董事会第八次 会议于 2025 年 12 月 19 日以现场结合通讯方式在公司 ...

Core Viewpoint - The company, Weisi Medical (688580.SH), plans to dispose of its current headquarters asset in Nanjing for a total price of 119 million yuan to optimize its asset structure and enhance resource allocation efficiency [1] Group 1: Asset Disposal - The asset being disposed of is located at 19 Ning Shuang Road, Yuhua District, Nanjing, including buildings and ancillary facilities [1] - The transaction is agreed upon with Jiangsu Yunzhi Hui Venture Capital Co., Ltd., and the total transfer price is inclusive of tax [1] Group 2: Strategic Benefits - The disposal is aimed at revitalizing existing assets, addressing issues related to idle resources after relocation, and reducing operational costs [1] - The funds recovered from this transaction will be used for the operation of the new headquarters and the development of core business, aligning with the company's long-term strategy and benefiting all shareholders [1]

Core Viewpoint - The company aims to optimize its asset structure and enhance resource allocation efficiency by disposing of its current headquarters asset, which is a building located at 19 Ning Shuang Road, Yuhua District, Nanjing, for a total price of 119 million yuan including tax [1] Group 1 - The disposal of the headquarters asset is intended to activate existing assets and address the issue of idle resources after relocation [1] - The transaction with Jiangsu Yunzhihui Venture Capital Co., Ltd. has been agreed upon, with a total transfer price of 119 million yuan [1] - This move is expected to reduce operational costs and recover funds for the operation of the new headquarters and the development of core business, aligning with the company's long-term strategy and benefiting all shareholders [1]

Group 1 - TikTok CEO Zhou Shuzi announced the establishment of a new joint venture, TikTok USDS Joint Venture LLC, to handle data protection and algorithm security in the U.S. while ByteDance retains control over e-commerce and advertising [1] - The new joint venture is expected to be finalized by January 22, 2026, and will focus on content review and software security [1] Group 2 - Hainan Free Trade Port officially launched its full island closure operation, leading to significant discounts on iPhone products, with prices reduced by over 2,000 yuan for certain models [3] - The iPhone 17 Pro Max 256GB version is priced at 9,299 yuan, which is 700 yuan cheaper than e-commerce platforms [3] Group 3 - OpenAI is in preliminary talks for a new funding round, aiming for a valuation of approximately $750 billion, with potential funding reaching hundreds of billions [3] - This valuation represents a 50% increase from the previous funding round in October 2022 [3] Group 4 - Elliott Investment Management has accumulated over $1 billion in shares of Lululemon and is advocating for a former Ralph Lauren executive to become the new CEO [12] - Lululemon's current market capitalization is around $25 billion [12] Group 5 - Apple announced adjustments to its iOS rules in Japan, allowing developers to use third-party app stores and payment methods, in compliance with new regulations [12] - This change enables developers to add alternative payment options within their apps [12] Group 6 - Honda confirmed a temporary suspension of production at its joint venture factory in China due to supply chain issues, specifically related to semiconductor shortages [16] - The suspension will last for three days starting December 29, 2023 [16] Group 7 - Xiaomi's founder announced the official release of the Xiaomi 17 Ultra next week, following leaked images of the device [7] - The new model is expected to generate significant consumer interest [7] Group 8 - Amazon is restructuring its AI team, integrating chip and model development under a new business unit led by a veteran from its cloud computing division [18] - This move aims to enhance Amazon's capabilities in artificial intelligence and maintain competitiveness in the market [18]

Group 1 - The core viewpoint of the news is that Weisi Medical has seen a stock price increase of 5.05%, reaching 46.98 CNY per share, with a total market capitalization of 4.499 billion CNY [1] - Weisi Medical, established on January 10, 2001, focuses on the research, production, and sales of rehabilitation medical devices, particularly in areas such as pelvic floor and postpartum rehabilitation, neurological rehabilitation, and mental rehabilitation [1] - The company's revenue composition includes: magnetic stimulation products (39.44%), consumables and accessories (19.42%), electrophysiological products (19.18%), laser radiofrequency products (10.26%), electrical stimulation products (8.42%), and others (3.28%) [1] Group 2 - From the perspective of fund holdings, Weisi Medical is a top ten holding of Huayin Fund Management, specifically in the Beixin Ruifeng Health Life Theme Flexible Allocation Fund (001056), which reduced its holdings by 15,000 shares to 75,000 shares, representing 4.13% of the fund's net value [2] - The Beixin Ruifeng Health Life Theme Flexible Allocation Fund (001056) was established on March 27, 2015, with a latest scale of 90.1431 million CNY, achieving a year-to-date return of 18.8% and a one-year return of 11.21% [2] - The fund manager, Pang Wenjie, has been in position for 5 years and 202 days, with the fund's total asset scale at 18.4 million CNY, achieving a best return of 44.46% and a worst return of -46.46% during his tenure [3]

Group 1 - The core decision of the board meeting was to conclude certain fundraising projects and permanently allocate the surplus funds to working capital [3][18] - The board meeting was held on December 17, 2025, with all seven directors present, and the decision was unanimously approved [2][4] - The surplus amount from the concluded projects is 36.9774 million yuan, which will be used to enhance the efficiency of fund utilization and support daily operations [9][16] Group 2 - The concluded fundraising projects include the Rehabilitation Equipment Assembly and Debugging Project and the Information Technology Construction Project [9][11] - The total fundraising raised was approximately 1.155 billion yuan, with a net amount of about 1.063 billion yuan after deducting issuance costs [10] - The surplus funds were generated due to effective cost control and management during the project implementation, leading to lower expenditures than initially planned [13][14] Group 3 - The decision to use surplus funds for working capital is aimed at optimizing resource allocation and enhancing operational efficiency, aligning with the company's long-term development strategy [16][17] - The audit committee and sponsor institution both support the decision, confirming it does not harm the interests of shareholders and complies with relevant regulations [17][19]

（文章来源：证券日报） 证券日报网讯 12月17日晚间，伟思医疗发布公告称，公司第四届董事会第七次会议审议通过《关于部 分募投项目结项并将节余募集资金永久补充流动资金的议案》。 ...

每经头条（nbdtoutiao）——"太空快递"来了？全国首个民营飞船成功"上天"！背后公司创始人：正积 极开发"中型货运飞船"低成本产品 2024年1至12月份，伟思医疗的营业收入构成为：医疗器械占比95.03%，其他占比3.79%，其他业务占 比1.18%。 截至发稿，伟思医疗市值为43亿元。 每经AI快讯，伟思医疗（SH 688580，收盘价：44.72元）12月17日晚间发布公告称，公司第四届第七次 董事会会议于2025年12月17日在公司会议室召开。会议审议了《关于部分募投项目结项并将节余募集资 金永久补充流动资金的议案》等文件。 （记者 王晓波） ...

长江证券承销保荐有限公司关于 南京伟思医疗科技股份有限公司部分募投项目结项并将节余募 集资金永久补充流动资金的核查意见 注3：最终转入公司自有资金账户的实际金额以资金转出当日该项目募集资金账户余额 为准； 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上市公司募集资金监管规则（2025年6月15日起施行）》《上海证券交 易所科创板上市公司自律监管指引第1号——规范运作》等有关规定，作为南京 伟思医疗科技股份有限公司（以下简称"伟思医疗"或"公司"）首次公开发行股票 并科创板上市项目的保荐机构，长江证券承销保荐有限公司（以下简称"长江保 荐"或"保荐机构"）对公司部分募投项目结项并将节余募集资金永久补充流动资金的 事项进行了认真、审慎的核查，并出具核查意见。核查的具体情况如下： 一、募集资金基本情况 | 发行名称 | 2020年南京伟思医疗科技股份有限公司首次公开发行股票 | | --- | --- | | 募集资金总额 | 115,471.70万元 | | 募集资金净额 | 106,298.70万元 | | 募集资金到账时间 | 2020年7月15日 | 根据中国证券监督管理委员 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2025-043 南京伟思医疗科技股份有限公司 关于部分募投项目结项并将节余募集资金永久补充 流动资金的公告 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意南京伟思医疗科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2020〕1213 号）文核准，公司向社会 公众公开发行人民币普通股（A 股）17,086,667 股，每股面值 1.00 元，每股发 1 行价格为 67.58 元。本次公开发行募集资金总额为 1,154,716,955.86 元，扣除 总发行费用 91,729,995.18 元（不含税），募集资金净额为 1,062,986,960.68 元。上述募集资金到位情况已经天衡会计师事务所（特殊普通合伙）审验，并于 2020 年 7 月 15 日出具了《验资报告》（天衡验字[2020]00075 号）。 注 1：康复设备组装调试项目节余募集资金金额包含累计收到的银行存款利 息扣除银行手续费的净额及购买理财产品收益共计 808.54 万元；信息化建设项 目项目节余募集资金金额包含累计收到的银行存款利息扣除银行手续费的净额 及购买理 ...